|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Psychosocial issues in evidence-based guidelines on inflammatory bowel diseases: A review显示文摘AIM:To study statements and recommendations on psychosocial issues as presented in international evidence-based guidelines on the management of inflammatory bowel diseases(IBD).METHODS:MEDLINE,guidelines International Network,National Guideline Clearing House and National Institute for Health and Care Excellence were searched from January 2006 to June 30,2013 for evidencebased guidelines on the management of IBD.RESULTS:The search yielded 364 hits.Thirteen guidelines were included in the review,of which three wereprepared in Asia,eight in Europe and two in the United States.Eleven guidelines made statements and recommendations on psychosocial issues.The guidelines were concordant in that mental health disorders and stress do not contribute to the aetiology of IBD,but that they can influence its course.It was recommended that IBD-patients should be screened for psychological distress.If indicated,psychotherapy and/or psychopharmacological therapy should be recommended.IBDcentres should collaborate with mental health care specialists.Tobacco smoking patients with Crohn’s disease should be advised to quit.CONCLUSION:Patients and mental health specialists should be able to participate in future guideline groups to contribute to establishing recommendations on psychosocial issues in IBD.Future guidelines should acknowledge the presence of psychosocial problems in IBD-patients and encourage screening for psychological distress. | Winfried Huser Gabriele Moser Petra Klose Antonina Mikocka-Walus | 2014 | World Journal of Gastroenterology2014，20，13： | 14 |
| 2 | Second European evidence-based consensus on the diagnosis and management of ulcerative colitis: Special situations显示文摘 | Gert Van Assche Axel Dignass Bernd Bokemeyer Silvio Danese Paolo Gionchetti Gabriele Moser Laurent Beaugerie Fernando Gomollón Winfried H?user Klaus Herrlinger Bas Oldenburg Julian Panes Francisco Portela Gerhard Rogler Jürgen Stein Herbert Tilg Simon Tra | 2012 | Journal of Crohn’s and Colitis2012，，： | 4 |
| 3 | Quality of life and sustainability: Toward person–environment congruity显示文摘 | Gabriel Moser | 2009 | Journal of Environmental Psychology2009，，3： | 1 |
| 4 | Azathioprine Treatment and Male Fertility in Inflammatory Bowel Disease显示文摘 | Clemens Dejaco Christian Mittermaier Walter Reinisch Christoph Gasche Thomas Waldhoer Heinz Strohmer Gabriele Moser | 2001 | Gastroenterology2001，，： | 1 |
| 5 | A Comparison of Feature Reduction Techniques for Classification of Hyperspectral Remote Sensing Data显示文摘 | Serpico Sebastiano B Dinca Massimo Melgani Farid Moser Gabriele | 2003 | Image and Signal Processing for Remote Sensing Ⅷ2003，4885，3： | 1 |
| 6 | Forecasting Austrian Inflation显示文摘 | Moser Gabriel Fabio Rumler Johann Scharler | 2007 | Economic Modelling2007，，24： | 1 |
| 7 | Classification of Very High Resolution SAR Images of Urban Areas Using Copulas and Texture in a Hierarchical Markov Random Field Model显示文摘 | AURLIE VOISIN VLADIMIR A KRYLOV GABRIELE MOSER | 2013 | IEEE Geoscience and Remote Sensing Letters2013，10，1： | 1 |
| 8 | Generalized Minimum-Error Thresholding for Unsupervised Change Detection from SAR Amplitude Imagery显示文摘 | GABRIELE Moser SEBASTIANO B S | 2006 | IEEE Transactions on Geoscience and Remote Sensing2006，44，10： | 1 |
| 9 | Safety and efficacy of purified clinoptilolite-tuff treatment in patients with irritable bowel syndrome with diarrhea:Randomized controlled trial显示文摘BACKGROUND Irritable bowel syndrome(IBS)is a highly prevalent gastrointestinal disorder with poor response to treatment.IBS with predominant diarrhea(IBS-D)is accompanied by abdominal pain as well as high stool frequency and urgency.Purified clinoptilolite-tuff(PCT),which is approved by the Food and Drug Administration for use as a dietary supplement with the brand name G-PUR®,has previously shown therapeutic potential in other indications based on its physical adsorption capacity.AIM To assess whether symptoms of IBS-D can be ameliorated by oral treatment with PCT.METHODS In this randomized,placebo-controlled,double-blind pilot study,30 patients with IBS-D diagnosis based on Rome IV criteria were enrolled.Following a 4-wk run-in phase,14 patients were randomized to receive a 12-wk treatment with G-PUR®(2 g three times daily),and 16 patients received placebo.The relief from IBS-D symptoms as measured by the proportion of responders according to the Subject’s Global Assessment(SGA)of Relief was assessed as the primary outcome.For the secondary outcomes,validated IBS-D associated symptom questionnaires,exploratory biomarkers and microbiome data were collected.RESULTS The proportions of SGA of Relief responders after 12 wk were comparable in both groups,namely 21%in the G-PUR®group and 25%in the placebo group.After 4 wk of treatment,36%of patients in the G-PUR®group vs 0%in the placebo group reported complete or considerable relief.An improvement in daily abdominal pain was noted in 94%vs 83%(P=0.0353),and the median number of days with diarrhea per week decreased by 2.4 d vs 0.3 d in the G-PUR®and placebo groups,respectively.Positive trends were observed for 50%of responders in the Bristol Stool Form Scale.Positive trends were also noted for combined abdominal pain and stool consistency response and the Perceived Stress Questionnaire score.Only 64%in the G-PUR®group compared to 86%in the placebo group required rescue medication intake during the study.Stool microbiome studies showed a minor increase in diversity in the G-PUR®group but not in the placebo group.No PCT-related serious adverse events were reported.CONCLUSION In this randomized,double-blind,placebo-controlled study,the PCT product,G-PUR®,demonstrated safety and clinical benefit towards some symptoms of IBS-D,representing a promising novel treatment option for these patients. | Karolina Anderle Michael Wolzt Gabriele Moser Bettina Keip Johannes Peter Claudia Meisslitzer Ghazaleh Gouya Michael Freissmuth Cornelius Tschegg | 2022 | World Journal of Gastroenterology2022，28，46： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员